Why Farbe Firma is the Leading Injectable Manufacturer in Barbados
Why Farbe Firma is the Leading Injectable Manufacturer in Barbados
Last Updated: 16 September 2026
TL;DR: Barbados has historically had no product registration requirement at all - the gate is commercial, not regulatory: an importer's licence, supplier registration with the Barbados Drug Service, a local agent and a place on the national formulary. That is now changing: the Barbados Medical Products Act, 2026 was passed in June 2026 and will introduce marketing authorisation, but as of PAHO's July 2026 report the new Authority was not yet operating and its guidance was still in draft.
Key Takeaways
The Pharmaceutical Country Profile published by the Barbados Ministry of Health with PAHO/WHO - the most recent available, and dated 2011 - records that legal provisions did not require marketing authorisation for pharmaceutical products, and that no mutual recognition mechanisms were in place.
What is required instead is an importer's licence, entry through authorised ports where products may be sampled, and GMP compliance by the manufacturer - including foreign manufacturers, though the same profile notes that Barbados does not publish its GMP requirements.
The reference-authority list that actually bites sits one level up, at CARPHA's Caribbean Regulatory System, and India's CDSCO is not on it - but WHO prequalification is expressly an accepted route, and WHO PQ is open to Indian manufacturers.
The Barbados Medical Products Act, 2026 creates a Barbados Medical Products Authority that will take over marketing authorisation. Enactment is not commencement, and the commencement position should be verified before anyone plans around it.
Introduction: What an Injectable Manufacturer in Barbados Actually Has to Clear
Barbados is a market of roughly 280,000 people, and it is one of the more unusual regulatory propositions in the Caribbean. Most country guides written for exporters open by explaining how to register a product. For Barbados that framing has historically been wrong, and an exporter who budgets for a registration dossier may be budgeting for the wrong thing while under-resourcing the thing that actually decides the outcome.
According to the Pharmaceutical Country Profile published by the Ministry of Health with PAHO and WHO - the most recent such profile available, and dated 2011 - Barbados did not require marketing authorisation, or product registration, for pharmaceutical products placed on its market, and no mutual recognition mechanisms were in place. It lists inspection, import control, licensing and quality control as functions the authority did perform. We flag the date deliberately: fifteen years is a long time, and a new Act has since passed.
What Sets a World-Class Injectable Manufacturer in Barbados Apart
If there is no dossier queue, what is there? On the evidence, a sequence: a licensed Barbadian importer; the manufacturer registered as a supplier with the Barbados Drug Service; a local agent, because the country profile records that international companies are required to bid through one; the product listed on the Barbados National Drug Formulary, some seven hundred medicines selected by a Drug Formulary Committee advisory to the Minister; and then success in a Drug Service competitive tender. Note the noun carefully - companies are registered with the Drug Service, not products. Conflating supplier registration with product registration is the single commonest error in this market.
Two features of that tender reward a manufacturer who can document itself. The profile records that a process exists to ensure the quality of products procured for the public sector, including prequalification of both products and suppliers, and that medicines are tested for public procurement prequalification - but not for product registration, which neatly locates where the real quality gate sits. It also records that there are no legal provisions giving priority to locally produced goods, which is favourable to an importer, and that at the time of writing 97.25 per cent of pharmaceuticals were supplied by foreign companies registered with the Drug Service.
Quality Systems Behind Every Batch Shipped to Barbados
Farbe Firma manufactures sterile injectables under WHO-GMP certification at ISO Class 5 aseptic filling, with in-house HPLC, GC, LAL endotoxin and Karl Fischer testing and ICH Q1A/Q1B stability programmes, and every batch ships with a certificate of analysis traceable to retained samples. That matters more here than in a registration market, because Barbados has no national quality-control laboratory of its own: the country profile records that testing is contracted out, naming the Caribbean Regional Drug Testing Laboratory and Experchem in Canada.
One requirement clearly does reach a foreign manufacturer. The profile records legal provisions requiring manufacturers, domestic and international alike, to comply with Good Manufacturing Practices - while noting in the same passage that GMP requirements are not published by the government. In practice a real obligation is measured against an unpublished standard, so the applicable expectation has to be established in dialogue with the Barbados Drug Service, and a supplier arriving with WHO-GMP certification and a complete site master file is arguing from a much stronger position than one who is not.
Why Farbe Firma is the Trusted Injectable Manufacturer in Barbados for Global Buyers
The lesson the Caribbean teaches repeatedly is that when the national gate is open, the exclusion is usually one level up. Barbados has no national list of recognised regulators, because it has had no registration system to attach one to. But a named reference-authority list does exist regionally, and an Indian manufacturer will meet it: CARPHA's Caribbean Regulatory System conducts abbreviated review only for products already approved by a designated reference authority - the PAHO regional reference authorities, the European Union or the United States - and India is not among them.
There is, however, an explicit way through, and it is the most commercially important sentence we can offer. CARPHA lists WHO prequalification alongside those agencies as a qualifying basis for review, and WHO prequalification is fully open to Indian manufacturing sites. Two honest limits belong with it: CARPHA's review is confined to products on the current WHO Essential Medicines List or the PAHO Strategic Fund list, and CARPHA only recommends favourably reviewed products to member states for consideration, leaving the decision national.
The forward-looking picture matters just as much. PAHO reported on 30 July 2026 that, following the passing of the Barbados Medical Products Act in mid-June, officials were working on draft guidance for product registration, draft accompanying regulations, staffing and systems for the new Authority, and had explored the use of reliance and recognition approaches. A Barbadian list of trusted regulators may well emerge from that work. None has been published, and which authorities will appear on it is not known - including to Barbados. What we can do is have a WHO-GMP file, a CTD/ACTD dossier and a prequalification pathway ready for the moment it is.
Explore Farbe Firma: Products / Global Reach / About Us
Frequently Asked Questions (FAQ)
Do I need to register my product with a Barbados medicines agency?
Historically, no - what is required is an importer's licence, with entry through authorised ports where products may be sampled and inspected. The caveat is important: the Barbados Medical Products Act, 2026 will introduce marketing authorisation under a new Authority, which as of July 2026 was not yet operating. Confirm the current position before you commit.
Is India on any Barbados list of approved source countries?
There is no such Barbadian list, because there has been no registration system to attach one to. At regional level there is a list and India is not on it: CARPHA's Caribbean Regulatory System names the PAHO reference authorities, the EU and the USA. CDSCO approval alone therefore does not unlock the CARPHA route, and it is worth adding that India's CDSCO appears on WHO's transitional listed-authority list with scope limited to vaccines, so a "stringent authority" argument built on it will not survive scrutiny for a non-vaccine injectable.
Will WHO Prequalification actually help me in Barbados?
For the CARPHA route, demonstrably yes - CARPHA expressly lists WHO prequalification alongside the reference agencies as a qualifying basis for abbreviated review, and that is the documented mechanism by which a product approved in India can enter the CARICOM abbreviated pathway. Whether Barbados itself gives WHO PQ any standalone weight is not documented, and since Barbados has had no registration system the question may not yet be a meaningful one.
What dossier format is required, and do I need a WHO CPP?
We found no Barbadian instrument prescribing CTD, ACTD or eCTD, and none requiring a WHO Certificate of a Pharmaceutical Product. That is a "not found" rather than a proven absence, and it is partly explained by there being no registration procedure yet to prescribe a format. Expect it to be settled by the draft guidance PAHO reports is being prepared. We could not establish which pharmacopoeias Barbados recognises, and we would not assume BP merely from the legal heritage.
How do I find current Drug Service tenders and supplier registration forms?
Directly, unfortunately. Throughout our research the Barbados Drug Service website was returning a server error rather than a page, so current tender documents, supplier registration forms, formulary editions and volumes could not be obtained from published sources. Prospective suppliers will need to approach the Drug Service and the Ministry of Health and Wellness directly. Note also that Barbados operates a general import licensing system under the Miscellaneous Controls Act Cap. 329 administered by the trade ministry, separate from any health requirement.
Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India.
Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog
Comments